1,725,388 research outputs found
Linked collectors and determiners for: Research database of Madagascar grasses compiled by Maria Vorontsova.
No full textNatural history specimen data linked to collectors and determiners held within, "Research database of Madagascar grasses compiled by Maria Vorontsova". Claims or attributions were made on Bionomia by volunteer Scribes, <a href="http://bionomia.net/dataset/15d76f87-6d16-4948-b4d5-f7d50a168aa6">https://bionomia.net/dataset/15d76f87-6d16-4948-b4d5-f7d50a168aa6</a> using specimen data from the dataset aggregated by the Global Biodiversity Information Facility, <a href="https://gbif.org/dataset/15d76f87-6d16-4948-b4d5-f7d50a168aa6">https://gbif.org/dataset/15d76f87-6d16-4948-b4d5-f7d50a168aa6</a>. Formatted as a Frictionless Data package
Linked collectors and determiners for: Research database of Madagascar grasses compiled by Maria Vorontsova.
No full textNatural history specimen data linked to collectors and determiners held within, "Research database of Madagascar grasses compiled by Maria Vorontsova". Claims or attributions were made on Bionomia by volunteer Scribes, <a href="http://bionomia.net/dataset/15d76f87-6d16-4948-b4d5-f7d50a168aa6">https://bionomia.net/dataset/15d76f87-6d16-4948-b4d5-f7d50a168aa6</a> using specimen data from the dataset aggregated by the Global Biodiversity Information Facility, <a href="https://gbif.org/dataset/15d76f87-6d16-4948-b4d5-f7d50a168aa6">https://gbif.org/dataset/15d76f87-6d16-4948-b4d5-f7d50a168aa6</a>. Formatted as a Frictionless Data package
Linked collectors and determiners for: New Zealand Arthropod Collection - Symbiota.
No full textNatural history specimen data linked to collectors and determiners held within, "New Zealand Arthropod Collection - Symbiota". Claims or attributions were made on Bionomia by volunteer Scribes, <a href="http://bionomia.net/dataset/38e0b5be-be0a-4948-ad2e-fb009652c5b3">https://bionomia.net/dataset/38e0b5be-be0a-4948-ad2e-fb009652c5b3</a> using specimen data from the dataset aggregated by the Global Biodiversity Information Facility, <a href="https://gbif.org/dataset/38e0b5be-be0a-4948-ad2e-fb009652c5b3">https://gbif.org/dataset/38e0b5be-be0a-4948-ad2e-fb009652c5b3</a>. Formatted as a Frictionless Data package
Linked collectors and determiners for: OSAC Peponapis dataset.
No full textNatural history specimen data linked to collectors and determiners held within, "OSAC Peponapis dataset". Claims or attributions were made on Bionomia by volunteer Scribes, <a href="http://bionomia.net/dataset/aa0ce746-9b9e-4948-92cf-80b38ed289f0">https://bionomia.net/dataset/aa0ce746-9b9e-4948-92cf-80b38ed289f0</a> using specimen data from the dataset aggregated by the Global Biodiversity Information Facility, <a href="https://gbif.org/dataset/aa0ce746-9b9e-4948-92cf-80b38ed289f0">https://gbif.org/dataset/aa0ce746-9b9e-4948-92cf-80b38ed289f0</a>. Formatted as a Frictionless Data package
Abstract 1168: Efficacy of the IRAK4 inhibitor CA-4948 in patient-derived xenograft models of diffuse large B cell lymphoma
No full textAbstract
IRAK4 kinase activity is required for toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling in a variety of myeloid and lymphoid cell types. Recruitment of IRAK4 to these receptors and its subsequent activation is facilitated by the MYD88 adaptor protein, which is mutated in ~22% of DLBCL cases. The MYD88 L265P activating mutation is found in ~30% of the activated B-cell (ABC) and ~6% of germinal center B-cell (GCB) subtypes of DLBCL and leads to constitutive activation of NF-κB signaling that is associated with worse prognosis. Thus, the development of small molecule inhibitors targeting IRAK4 is an attractive anticancer strategy for MYD88 mutation-containing cancers such as DLBCL.
We are developing an IRAK4 inhibitor, CA-4948, as a therapeutic agent for hematological cancers with dysregulated TLR/MYD88/IRAK4 signaling. CA-4948 (previously AU-4948) is a selective and potent IRAK4 kinase inhibitor with in vivo activity in a TLR4-induced cytokine release model. CA-4948 exhibits favorable DMPK properties, oral bioavailability, and is well tolerated in mice. Furthermore, CA-4948 was previously shown to exhibit dose-dependent efficacy in ABC-DLBCL MYD88-L265P xenograft tumor models using cell lines OCI-LY3 and OCI-LY10.
Here, we report the efficacy results from testing CA-4948 in a panel of well characterized, patient-derived DLBCL tumor xenograft (PDX) mouse models. CA-4948 exhibited the greatest efficacy in four of the five ABC-DLBCL PDX models tested as compared to GBC-DLBCL and ABC/GCB DLBCL PDX models. Furthermore, CA-4948 was efficacious in ABC-DLBCL PDX tumors containing activating mutations in both TLR/IL-1R and BCR signaling pathways (MYD88 and CD79B double mutants). Interestingly, the one ABC-DLBCL PDX model that failed to respond to CA-4948 treatment contained a MYD88 L265P mutation as well as a BCL6 translocation. While this particular PDX model was resistant to CA-4948, and showed a weak anti-tumor response to single-agent ibrutinib, the combination treatment of ibrutinib and CA-4948 exhibited a synergistic tumor growth inhibition effect. In summary, CA-4948 exhibited anti-tumor activity in ABC-type DLCBL PDX tumor models including those containing combinations of activating mutations in the TLR/IL-1R and BCR signaling pathways. These results underscore the therapeutic potential of IRAK4 kinase inhibition by CA-4948, as a single-agent or in combination with BCR inhibitors, for the treatment of DLBCL.
Citation Format: Robert N. Booher, Maria Elena Samson, Guang-Xin Xu, Hongsheng Cheng, David P. Tuck. Efficacy of the IRAK4 inhibitor CA-4948 in patient-derived xenograft models of diffuse large B cell lymphoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1168. doi:10.1158/1538-7445.AM2017-1168</jats:p
Going Beyond Counting First Authors in Author Co-citation Analysis
No full textThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
No full text“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Appropriate Similarity Measures for Author Cocitation Analysis
No full textWe provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
Dispelling the Myths Behind First-author Citation Counts
No full textWe conducted a full-scale evaluative citation analysis study of scholars in the XML research field to explore just how different from each other author rankings resulting from different citation counting methods actually are, and to demonstrate the capability of emerging data and tools on the Web in supporting more realistic citation counting methods. Our results contest some common arguments for the continued
use of first-author citation counts in the evaluation of scholars, such as high correlations between author rankings by first-author citation counts and other citation
counting methods, and high costs of using more realistic citation counting methods that are not well-supported by the ISI databases. It is argued that increasingly available digital full text research papers make it possible for citation analysis studies to go beyond what the ISI databases have directly supported and to employ more
sophisticated methods
- …
